Ascendis Pharma AS (NAS:ASND)
$ 124.33 -2.22 (-1.75%) Market Cap: 7.43 Bil Enterprise Value: 7.88 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Q3 2023 Ascendis Pharma A/S Earnings Call Transcript

Nov 07, 2023 / 09:30PM GMT
Release Date Price: $96.15 (+1.84%)
Operator

Hello, and welcome to the Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast. (Operator Instructions)

I would now like to hand the conference over to Tim Lee, Senior Director, Investor Relations, Ascendis Pharma. You may begin.

Timothy J. Lee;S;Senior Director of IR
Ascendis Pharma A

/-

Thank you, operator, and thank you, everyone, for joining our third quarter 2023 financial results conference call. I'm Tim Lee, Senior Director of Investor Relations at Ascendis Pharma.

Joining me on the call today is Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Executive Vice President and Chief Financial Officer; and Dr. Stina Singel, Executive Vice President and Head of Clinical Development Oncology.

Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot